Nalaganje...
Risk factors for immune-related adverse events associated with anti-PD-1 pembrolizumab
We investigated risk factors for immune-related adverse events (irAEs) in patients treated with anti-programmed cell death protein1 antibody pembrolizumab. A retrospective medical record review was performed to identify all patients who received at least one dose of pembrolizumab at Samsung Medical...
Shranjeno v:
| izdano v: | Sci Rep |
|---|---|
| Main Authors: | , , , , , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Nature Publishing Group UK
2019
|
| Teme: | |
| Online dostop: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6773778/ https://ncbi.nlm.nih.gov/pubmed/31575933 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41598-019-50574-6 |
| Oznake: |
Označite
Brez oznak, prvi označite!
|